Cancer pain

Current Opinion in Supportive and Palliative Care

Volumn 7, Issue 2, 2013, Pages 139-143

  Mercadante, Sebastiano ^a,b  

^a LA MADDALENA CANCER CENTER   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Analgesics; Cancer pain; Opioids

Indexed keywords

ANALGESIC AGENT; NARCOTIC ANALGESIC AGENT;

ANALGESIA; BREAKTHROUGH PAIN; DRUG SUBSTITUTION; GENETICS; HUMAN; METHODOLOGY; NEOPLASM; PAIN; REVIEW;

ANALGESICS; ANALGESICS, OPIOID; BREAKTHROUGH PAIN; DRUG SUBSTITUTION; HUMANS; NEOPLASMS; PAIN; PAIN MANAGEMENT;

EID: 84877974123     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e3283610433     Document Type: Review

References (45)

1. Stockler MR, Wilcken NR. Why is management of cancer pain still a problem? J Clin Oncol 2012; 30: 1907-1908.
2. Higginson IJ, Gao W. Opioid prescribing for cancer pain during the last 3 months of life: associated factors and 9-year trends in a nationwide United Kingdom cohort study. J Clin Oncol 2012; 30: 4373-4379.
3. Mercadante S, Fulfaro F. World Health Organization guidelines for cancer pain: a reappraisal. Ann Oncol 2005; 16 (Suppl. 4): 132-135.
4. Koyyalagunta D, Bruera E, Solanki DR, et al. A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Physician 2012; 15 (3 Suppl. ):ES39-ES58.
5. Caraceni A, Hanks GW, Kaasa S, et al. Use of opioid analgesic in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13: 58-68.
6. Mercadante S. Predictive factors and opioid responsiveness in cancer pain. Eur J Cancer 1998; 34: 627-631.
7. Bruera E, MacMillan K, Hanson J, MacDonald R. The Edmonton Staging System for cancer pain: preliminary report. Pain 1989; 37: 203-209.
8. Fainsinger R, Fairchild A, Nekolaichuk C, et al. Is pain intensity a predictor of the complexity of cancer pain management? J Clin Oncol 2009; 27: 585-590.
9. Knudsen AK, Aass N, Heitzer E, et al. , European Palliative Care Research Collaborative (EPCRC). Interviews with patients with advanced cancer: another step towards an international cancer pain classification system. Support Care Cancer 2012; 20: 2491-2500.
10. Knudsen AK, Brunelli C, Klepstad P, et al. Which domains should be included in a cancer pain classification system? Analyses of longitudinal data. Pain 2012; 153: 696-703.
11. Mercadante S. Cancer pain undertreatment and prognostic factors. Pain 2012; 153: 1770-1771.
12. Yennurajalingam S, Kang JH, Hui D, et al. Clinical response to an outpatient palliative care consultation in patients with advanced cancer and cancer pain. J Pain Symptom Manage 2012; 44: 340-350.
13. Mercadante S, Gebbia V, David F, et al. Does pain intensity predict a poor opioid response in cancer patients? Eur J Cancer 2011; 47: 713-717.
14. Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol 2011; 80: 460-465.
15. Caraceni A, Bertetto O, Labianca R, et al. Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI - Italian questionnaire for intense episodic pain. J Pain Symptom Manage 2012; 43: 833-841.
16. Mercadante S, Villari P, Ferrera P, Casuccio A. Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manage 2004; 28: 505-510.
17. Mercadante S. Breakthrough pain: on the road again. Eur J Pain 2009; 13: 329-330.
18. Davies A, Zeppetella G, Andersen S, et al. Multicentre European study of breakthrough cancer pain: characteristics and patient perceptions of current and potential management strategies. Eur J Pain 2011; 15: 756-763.
19. Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs 2012; 72: 181-190.
20. Davies AD, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the science committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009; 13: 331-338.
21. Mercadante S, Gatti A, Porzio G, et al. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin 2012; 28: 963-968.
22. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev 2006; 32: 304-315.
23. Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med 2011; 25: 504-515.
24. Mercadante S, Ferrera P, Villari P, et al. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage 2009; 37: 632-641.
25. Benitez-Rosario M, Salinas-Martin A, Aguirre-Jaime A, et al. Morphine-methadone opioid rotation in cancer patients: analysis of dose predicting factors. J Pain Symptom Manage 2009; 37: 1061-1068.
26. Mercadante S, Casuccio A, Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol 1999; 17: 3307-3312.
27. Bruera E, Pereira J, Watanabe S, et al. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996; 78: 852-857.
28. Lawlor R, Turner K, Hanson J, Bruera E. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain 1997; 72: 79-85.
29. Lawlor P, Turner K, Hanson J, Bruera E. Dose ratio between morphine and methadone in patients with cancer pain. A retrospective study. Cancer 1998; 82: 1167-1173.
30. Moksnes K, Dale O, Rosland JH, et al. How to switch from morphine or oxycodone to methadone in cancer patients? A randomized clinical phase II trial. Eur J Cancer 2011; 47: 2463-2470.
31. Mercadante S. Stop and go strategy for opioid switching requires flexibility. Eur J Cancer 2012; 48: 944-945.
32. Mercadante S. Switching to methadone: a ten years experience of 345 patients in an acute palliative care unit. Pain Med 2012; 13: 399-404.
33. Mercadante S, Porzio G, Ferrera P, et al. Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin 2012; 28: 1775-1779.
34. Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 2012; 11:CD003351.
35. Hardy J, Quinn S, Fazekas B, et al. Randomized, double-blind, placebocontrolled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol 2012; 30: 3611-3617.
36. Deer TR, Smith HS, Burton AW, et al. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician 2011; 14:E283-E312.
37. Dupoiron D, Bore F, Lefebvre-Kuntz D, et al. Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol. Pain Physician 2012; 15: 395-403.
38. Alicino I, Giglio M, Manca F, et al. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice. Pain 2012; 153: 245-249.
39. Mishra S, Bhatnagar S, Goyal GN, et al. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Care 2012; 29: 177-182.
40. Choi TY, Lee MS, Kim TH, et al. Acupuncture for the treatment of cancer pain: a systematic review of randomised clinical trials. Support Care Cancer 2012; 20: 1147-1158.
41. Hurlow A, Bennett MI, Robb KA, et al. Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults. Cochrane Database Syst Rev 2012; 3:CD006276.
42. Lötsch J. Genetic variability of pain perception and treatment-clinical pharmacological implications. Eur J Clin Pharmacol 2011; 67: 541-551.
43. Rauch SM, Gonzalez BD, Clark MM, et al. SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors. Lung Cancer 2012; 77: 217-223.
44. Klepstad P, Fladvad T, Skorpen F, et al. , European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care Research Network. Influence from genetic variability on opioid use for cancer pain: a European Genetic Association study of 2294 cancer pain patients. Pain 2011; 152: 1139-1145.
45. Andreassen TN, Eftedal I, Klepstad P, et al. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A crosssectional multicentre study. Eur J Clin Pharmacol 2012; 68: 55-64.